http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Molecular Characterization of Two Strains of Porcine Group C Rotavirus
Sung-Geun Lee,Soo-Hyun Youn,Mi-Hwa Oh,Ok-Jae Rhee,오상석,백순영 한국미생물학회 2011 The journal of microbiology Vol.49 No.6
Group C rotaviruses are an important cause of acute gastroenteritis in humans and animals. Fecal samples were collected from a porcine herd in July, 2009. Group C rotavirus RNA was detected using RT-PCR for the VP6 gene. The identified strain was further characterized by sequencing and phylogenetic analysis of the partial VP4, and complete VP6 and VP7 gene sequences. The partial VP4 and complete VP6 gene sequences of the CUK-5 strain were most closely related to those of the CUK-6 strain of group C rotaviruses. Phylogenetic analysis of the VP7 gene of the 2 strains (CUK-5 and CUK-6) and reference strains of group G rotavirus by the neighbor-joining method also confirmed that CUK-5 and CUK-6 belonged to type G5 and G1 strains, respectively. This study provides useful data for the prediction of newly appearing variants of porcine group C rotaviruses in neighboring countries through comparisons with GCRVs and fundamental research for vaccine development.
( Jae Cheol Moon ),( Da Hee Heo ),( Sang Hoon Han ),( Ji Young Rhee ),( Jung Mi Kwon ),( Woo Kun Kim ) 대한내과학회 2013 대한내과학회 추계학술대회 Vol.2013 No.1
A 92-year-old woman visited hospital with edema of both lower extremities. Computed tomography showed Inferior vena cava (IVC) compressed by huge hepatic cyst. Massive IVC thrombosis and pulmonary thromboembolism (PTE) were also observed. Medical treatment rather than radiologic intervention was preferred due to elderly age and poor performance status of the patient. IVC thrombosis and PTE were disappeared after anticoagulation therapy for 6months. By our knowledge, this is first report of IVC thrombosis caused by congenital hepatic cyst in English literature.
HspA and HtpG Enhance Thermotolerance in the Cyanobacterium, Microcystis aeruginosa NIES-298
( Jae Sung Rhee ),( Jang Seu Ki ),( Bo Mi Kim ),( Soon Jin Hwang ),( Ik Young Choi ),( Jae Seong Lee ) 한국미생물 · 생명공학회 2012 Journal of microbiology and biotechnology Vol.22 No.1
Heat shock proteins (Hsps) play a key role in the cellular defense response to diverse environmental stresses. Here, the role of Hsp genes in the acquisition of thermotolerance in the cyanobacterium Microcystis aeruginosa NIES-298 was investigated. Twelve Hsp-related genes were examined to observe their modulated expression patterns at different temperatures (10, 15, 25, and 35oC) over different exposure periods. HspA and HtpG transcripts showed an up-regulation of expression at low temperatures (10 and 15oC) and high temperature (35oC), compared with the control (25oC). To examine their effects upon thermotolerance, we purified recombinant HspA and HtpG proteins. During a thermotolerance study at 54oC, the HspA-transformed bacteria showed increased thermotolerance compared with the control. HtpG also played a role in the defense response to acute heat stress within 30 min. These findings provide a better understanding of cellular protection mechanisms against heat stress in cyanobacteria.
Sung-Hun Lim,Jin-Seok Kim,Jong-Fil Moon,Jae-Chul Kim,Sang-Bong Rhee,Chul-Hwan Kim,Ok-Bae Hyun IEEE 2009 IEEE transactions on applied superconductivity Vol.19 No.3
<P>We suggested that the neutral line is a more effective location for a superconducting fault current limiter (SFCL) in a three-phase power system. To confirm it, we analyzed the quench and recovery characteristics of SFCL applied into the neutral line in cases of non-symmetrical ground faults, such as single line-to-ground and double line-to-ground faults. Through a comparative analysis based on the experimental results for two SFCLs applied either to the neutral line or to the three-phase power line, it was confirmed that the SFCL applied into the neutral line of the power system was more advantageous from the viewpoint of both the practical use of the SFCL and the SFCL's coordination with other related protective devices in the power system.</P>
Rhee, Moo-Yong,Baek, Sang Hong,Kim, Weon,Park, Chang Gyu,Park, Seung Woo,Oh, Byung-Hee,Kim, Sang-Hyun,Kim, Jae-Joong,Shin, Joon-Han,Yoo, Byung-Su,Rim, Se-Joong,Ha, Jong-Won,Doh, Joon Hyung,Ahn, Youngk Dove Medical Press 2015 Drug design, development and therapy Vol.9 No.-
<P><B>Background</B></P><P>The study reported here compared the blood pressure (BP)-lowering efficacy of fimasartan alone with that of fimasartan/hydrochlorothiazide (HCTZ) combination in patients whose BP goal was not achieved after 4 weeks of treatment with once-daily fimasartan 60 mg.</P><P><B>Methods</B></P><P>Patients with sitting diastolic blood pressure (siDBP) ≥90 mmHg with 4 weeks of once-daily fimasartan 60 mg were randomly assigned to receive either once-daily fimasartan 60 mg/HCTZ 12.5 mg or fimasartan 60 mg for 4 weeks. After 4 weeks, the dose was increased from fimasartan 60 mg/HCTZ 12.5 mg to fimasartan 120 mg/HCTZ 12.5 mg or from fimasartan 60 mg to fimasartan 120 mg if siDBP was ≥90 mmHg.</P><P><B>Results</B></P><P>Of the 263 randomized patients, 256 patients who had available efficacy data were analyzed. The fimasartan/HCTZ treatment group showed a greater reduction of siDBP compared to the fimasartan treatment group at Week 4 (6.88±8.10 mmHg vs 3.38±7.33, <I>P</I>=0.0008), and the effect persisted at Week 8 (8.67±9.39 mmHg vs 5.02±8.27 mmHg, <I>P</I>=0.0023). Reduction of sitting systolic BP in the fimasartan/HCTZ treatment group was also greater than that in the fimasartan treatment group (at Week 4, 10.50±13.76 mmHg vs 5.75±12.18 mmHg, <I>P</I>=0.0069 and, at Week 8, 13.45±15.15 mmHg vs 6.84±13.57 mmHg, <I>P</I>=0.0007). The proportion of patients who achieved a reduction of siDBP ≥10 mmHg from baseline and/or a mean siDBP <90 mmHg after 4 weeks of treatment was higher in the fimasartan/HCTZ treatment group than in the fimasartan treatment group (53.6% vs 39.8%, <I>P</I>=0.0359). The overall incidence of adverse drug reaction was 11.79% with no significant difference between the treatment groups.</P><P><B>Conclusion</B></P><P>The combination treatment of fimasartan and HCTZ achieved better BP control than fimasartan monotherapy, and had comparable safety and tolerance to fimasartan monotherapy.</P>